Go/No-Go in 4 weeks: a high-stakes pharma product validation
Facing a multi-million-dollar production commitment, a Top-20 pharmaceutical manufacturer needed cross-market validation from healthcare professionals (HCPs) — one of the hardest-to-reach cohorts in research — before a closing investment window. Qualz.ai delivered the full engagement end-to-end: from kickoff and study design, to 155 in-depth, native-language HCP interviews across the U.S. and Germany, to AI + analyst synthesis and actionable insights for evidence-based decision-making — all in 28 days.
Client: Top-20 pharmaceutical manufacturer
Validate before you commit.
- Validate product acceptance with HCPs who would actually prescribe it — not proxy audiences.
- Compare directly against current standard-of-care and competitor offerings, in real decision context.
- Capture market-specific signal in the U.S. and Germany simultaneously — not sequentially.
- Deliver decision-ready insight ahead of the capex commitment, not after.
High-stakes decision, slow research reality.
- Time. Traditional qual delivers first findings in months — and the investment window was 90 days wide.
- Cost. Live moderators, dual-language transcription, and per-market analyst teams compound across two geographies.
- Scheduling. Coordinating 150+ specialists across U.S. and Central European time zones loses weeks to calendars alone.
- Window. A 90-day capex decision window left no room for sequential market fielding.
HCPs are notoriously hard to recruit. We met them where they are.
Healthcare professionals are one of the most difficult cohorts in qualitative research — guarded by gatekeepers, locked into clinical schedules, and skeptical of generic outreach. Qualz.ai's async, AI-moderated platform let specialist HCPs participate on their own time, in their own language, without booking a single live moderator slot — collapsing the recruitment-and-fielding bottleneck that traditionally caps sample size and breadth.
One study, two markets, one platform.
AI-designed interview flow
Faster iteration across drafts and stakeholder reviews, without compromising probing depth.
Image-based product evaluation
Real decision context. HCPs reacted to packaging, dosing, and positioning — not abstract concepts.
Comparative competitive prompts
Direct positioning signals. Each respondent assessed the product against named competitors and SOC.
Native multilingual fielding
No translation bias. German respondents in German, English in English — analyzed natively.
Sixteen weeks of work, compressed into four.
| Phase | Traditional | Qualz.ai | Time saved |
|---|---|---|---|
| Design & stakeholder alignment | 2–3 weeks | 4 days · AI-assisted iteration | ~2 weeks |
| Recruit & schedule HCPs | 4–6 weeks | 3 days · panel-on-demand | ~5 weeks |
| Fielding (155 IDIs, 2 markets) | 6–8 weeks | 14 days · async, parallel | ~5 weeks |
| Transcription & translation | 1–2 weeks | Real-time · native-language | ~1.5 weeks |
| Analysis, coding & synthesis | 3–4 weeks | 5 days · AI + analyst review | ~3 weeks |
| Total | 14–20 weeks | 4 weeks | 10–16 weeks |
Decision-grade insight, ahead of the investment window.
Findings delivered 10+ weeks ahead of the traditional qual timeline — inside the capex decision window.
Eliminated per-market live moderation, dual-language transcription, and parallel analyst teams.
Cross-market HCP validation gave leadership the confidence to commit on schedule, not defer.
Speed did not come at the expense of depth. Each IDI averaged 22 minutes of substantive response, with comparative probes against named competitors and current standard-of-care. Native-language fielding eliminated translation residue. Every synthesis round was reviewed by a senior qualitative analyst before findings became stakeholder-facing.
Have a decision waiting on research?
See how Qualz.ai compresses your next study from quarters to weeks — without compromising rigor. Book a 30-minute demo and get a custom timeline + cost estimate for your next project.
